All Posts

In this video we go over what biotech / biopharma stock catalyst events are and how they give investors opportunity. Manny Vacchiano with the BiopharmIQ team goes over: - Clinical trial events - Revenue/sales report outs - Corporate events - Legal actions/events Discover 100's of upcoming catalyst events on our biopharma research platform (free 30 day trial no cc required) : https://www.bpiq.com/ Catalyst events, biotech investing, stocks, due diligence, FDA, catalyst calenda

On 10/31/23 the FDA convened the 1st AdCom... 🏆 for a therapeutic made using gene editing exa-cel - from $VRTX / $CRSP In its Briefing Document, FDA provided an overview of genome editing, especially using CRISPR/Cas9 📸 📸 At the AdCom, to educate AdCom members ... FDA hired a gene editing KOL Fyodor Urnov (UC Berkeley) who gave a gene editing tutorial to the AdCom members Want to understand gene editing better? Watch the gene editing presentation by Fyodor Urnoff of UC Ber

BACKGROUND

SUMMARY

SUMMARY Hedge fund holdings can help you discover new investment ideas We identified & follow the top biopharma-focused hedge funds Q3 hedge fund holdings reports were released on ~11/14/23 This report focuses on top holdings of top biopharma hedge funds as of 9/30/23 Top Biopharma Hedge Funds At BPIQ we identified the top smid-cap biopharma-focused hedge funds ^1. We updated our database of holding and other info re: these funds with their recently-released data for holdings

Great that $XBI is up this week on Fed pause But XBI is still very low (in the $60s) Here’s 2 ways to make $$ in this long-term biotech bear market (See 👇) 1) Smid-cap biopharma M&A targets 2) M&A arbitrages STRATEGY 1 Invest in biopharma companies that are M&A targets ⇒ Cannot know for certain which biopharma Co's will get acquired ⇒ So focus on companies with attributes that make them M&A targets • Especially since biopharma M&A is very active 📸 • -1 key attri

Check out the gene editing presentation @ the ~30 min to ~50 min mark of the 10/31/23 VRTX AdCom by Fyodor Urnoff of UC Berkeley Available at the following Link: https://www.youtube.com/watch?v=M90IjjxOdQg&t=20970s Posted 11/1/23 This article is NOT legal, investment or tax advice. Please do your own diligence before making any investment decisions.

For FDA decision on $SRPT ELEVIDYS (ELEV) DMD gene therapy Currently ... ELEV has conditional approval for 4-5 yr olds only SPRT wants full approval & expanded label for all DMD pts FDA is faced with challenge: Hold a hard line on the 1' endpoint? 17 question NSAA test (rated as 0, 1, or 2) 📸 ELEV missed 1' endpoint 📸 Or give SRPT the benefit of the doubt? DMD trials are very hard to run 1 time gene therapy with well founded MOA ELEV was Directionally favorable for all key

At BPIQ, our goal is to help you make money investing in smid-cap biopharma stocks

See our post "Two Strategies to Make Money in a Biopharma Down Market" for key strategies to make money regardless of whether XBI is in an upward or downward trend